Top-News

Apollo Endosurgery Aktie

Aktie
WKN:  A2DJ26 ISIN:  US03767D1081 US-Symbol:  APEN
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
27,04 Mio.
Marktkapitalisierung *
-
Streubesitz
32,31%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 30.07.2021

Apollo Endosurgery News

29.11.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc.
SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc. PR Newswire
29.11.22 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SBCF, PFHD, SMBC
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SBCF, PFHD, SMBC PR Newswire
29.11.22 - PR Newswire
Shareholder Alert: Ademi LLP investigates whether Apollo Endosurgery, Inc. has obtained a Fair Price in its Transaction with Boston Scientific
Shareholder Alert: Ademi LLP investigates whether Apollo Endosurgery, Inc. has obtained a Fair Price in its Transaction with Boston Scientific PR Newswire
29.11.22 - PR Newswire
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc. PR Newswire
01.09.20 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Apollo Endosurgery, Inc.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Apollo Endosurgery, Inc. PR Newswire
08.09.16 - PR Newswire
Apollo Endosurgery and Lpath Sign Merger Agreement
Apollo Endosurgery and Lpath Sign Merger Agreement Merger to create NASDAQ-​listed medical device company focused on developing and commercializing minimally-​invasive ...
20.06.16 - PR Newswire
Lpath Awarded Department of Defense Grant for Traumatic Brain Injury Pain Study
Lpath Awarded Department of Defense Grant for Traumatic Brain Injury Pain Study PR Newswire
09.06.16 - PR Newswire
Lpath Announces 1-for-14 Reverse Stock Split
Lpath Announces 1-for-14 Reverse Stock Split PR Newswire
19.04.16 - PR Newswire
Lpath Reports Favorable Results from Phase 1 Study of Lpathomab
Lpath Reports Favorable Results from Phase 1 Study of Lpathomab PR Newswire
01.02.16 - PR Newswire
Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study
Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study Lpathomab is well-​tolerated at all doses tested in healthy volunteers PR Newswire
05.11.15 - PR Newswire
Lpath to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
Lpath to Present Nexus Phase 2 Study Data in Wet Age-​Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day ...
29.09.15 - PR Newswire
Lpath Appoints Gary Atkinson Interim Chief Executive Officer
Lpath Appoints Gary Atkinson Interim Chief Executive Officer PR Newswire
15.09.15 - PR Newswire
Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab
Lpath Initiates First-​in-Human Dosing in Phase 1 Clinical Trial of Lpathomab PR Newswire
11.08.14 - PR Newswire
Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
Lpath to Present at 34th Annual Canaccord Genuity Growth Conference PR Newswire
24.07.14 - PR Newswire
Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP
Lpath Reports Interim Data From Phase 2a Study for Anti-​Cancer Drug, ASONEP Based on encouraging progression-​free survival data, Lpath extends the study to a second cohort ...
02.06.14 - PR Newswire
Lpath to Present Trial-in-Progress Poster at ASCO Describing the ASONEP Phase 2 Clinical Trial in RCC Patients
Lpath to Present Trial-​in-Progress Poster at ASCO Describing the ASONEP Phase 2 Clinical Trial in RCC Patients Lpath will also host an investor call and webcast on Wednesday, ...
05.05.14 - PR Newswire
Lpath Lands Fast-Track SBIR Grant from the NIH for Traumatic Brain Injury Treatment
Lpath Lands Fast-​Track SBIR Grant from the NIH for Traumatic Brain Injury Treatment SBIR Grant from the National Institutes of Neurological Diseases and Stroke Provides Funds ...
30.04.14 - PR Newswire
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models The Department of Defense's WRAIR will study Lpath's ...
25.04.14 - PR Newswire
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models
Lpath and Walter Reed Army Institute for Research Begin Efficacy Study Using Lpathomab in Traumatic Brain Injury Models The Department of Defense's WRAIR will study Lpath's ...
05.03.14 - PR Newswire
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models Publication Further Validates Lpath's Approach to Targeting ...

Newssuche

Videos

newspaper
09:05 Uhr
Technical Trading: 10yr T Notes Long-​Chance
10yr T-Notes Long Typ: Turbo Open End WKN: JL04UC Hebel: 6,86 Laufzeit: OpenEnd Einstieg: Market ... Mehr »